Developer docs
API playgroundTry for free, no card

Search company profiles

Rinri Therapeutics

Full company profile

uuid0000w1w

Namestring
Rinri Therapeutics
Legal namestring
Rinri Therapeutics Ltd
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Rinri Therapeutics is a clinical-stage biotechnology company developing first-in-class regenerative cell therapies for sensorineural hearing loss (SNHL). The company is headquartered at the Innovation Centre in Sheffield, United Kingdom, and was spun out of the University of Sheffield in 2019 based on Professor Marcelo Rivolta's foundational research into sensory stem cell biology, originally published in Nature in 2012. Around 90% of all hearing loss is sensorineural, and Rinri targets the neural component - auditory neuron damage - which cannot be addressed by existing hearing aids or cochlear implants. The company addresses a UK patient population estimated at 2.3 million with presbycusis and 13.5 million with auditory neuropathy spectrum disorder, within a global market of 430 million people with disabling hearing loss projected to reach 2.5 billion by 2050.

The company's core technology is the proprietary OSPREY platform, which reprograms pluripotent cells into early-stage auditory cells (otic neural progenitors) for therapeutic use. Lead product Rincell-1 comprises auditory neuron cells one developmental stage from maturity, derived from stem cells donated by a single human donor and stored in a stem cell bank. Rincell-2 targets the same neural replacement mechanism via alternative starting cells, while Rincell-3 focuses on auditory hair cell replacement. Preclinical work demonstrated approximately 40% hearing threshold improvement, and the company has funded research verifying safe surgical access to the central core of the human cochlea through an international coalition. Rincell-1 received UK MHRA approval for first-in-human trials in July 2025, MHRA Innovation Passport under ILAP, and FDA RMAT designation.

Rinri is currently pre-revenue with no commercial product pricing, generating no product revenue and operating with disclosed funding of £11.4 million in equity (a £1.4m seed round in May 2019 co-led by Boehringer Ingelheim Venture Fund and UCB Ventures, plus a £10m Series round in April 2021 from existing investors and the UK Government Future Fund) supplemented by Innovate UK grants and a $1m Grand Prize in October 2025. The go-to-market model is enterprise-direct: clinical trial delivery is conducted in partnership with NHS Cochlear Implant Programmes, and future commercialisation will target NHS trusts, hospitals, ENT surgeons, and audiologists in the UK, with regulatory pursuit in the US via FDA RMAT. Strategic ecosystem partners include Cell and Gene Therapy Catapult (manufacturing), Advanced Bionics (cochlear implant technology), NIHR Nottingham Biomedical Research Centre, and the University of Sheffield's Rivolta Laboratory.

Short descriptiontext

Rinri Therapeutics is a Sheffield-based, clinical-stage biotechnology company developing first-in-class regenerative cell therapies to reverse sensorineural hearing loss, with lead product Rincell-1 entering first-in-human trials for adults eligible for cochlear implants.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSheffield, United Kingdom
HQ citystring
Sheffield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative cell therapy, hearing loss treatment, stem cell therapy, otic neural progenitors, sensorineural hearing loss
Industry2 codes
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Regenerative Cell Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Therapeutic Product Revenue
TypeOne Time License
Description

Rinri Therapeutics is a clinical-stage company developing regenerative cell therapies. No revenue is currently generated. The company plans to commercialize its pipeline of cell therapy products (Rincell-1, Rincell-2, Rincell-3) for the treatment of sensorineural hearing loss once approved.

rinri-therapeutics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1OSPREY
Description

Proprietary platform for auditory cell development and manufacturing, enabling the development of a portfolio of differentiated products to tackle different aspects of hearing loss.

rinri-therapeutics.com
+3 more records
Core offering1 text field

Rinri Therapeutics develops regenerative cell therapies for sensorineural hearing loss, with lead product Rincell-1 (otic neural progenitors derived from human pluripotent stem cells) designed to regenerate auditory neurons and restore cochlear connections. The portfolio is built on the proprietary OSPREY platform and targets an unmet medical need unaddressed by hearing aids or cochlear implants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Improved hearing threshold by approximately 40% in preclinical studies
+3 more records
Product overview1 text field

Rinri Therapeutics is developing a portfolio of first-in-class regenerative cell therapies for sensorineural hearing loss based on its proprietary OSPREY technology platform. The lead product, Rincell-1, is an otic neural progenitor cell therapy designed to regenerate auditory neurons and is currently in first-in-human clinical trials. The portfolio includes Rincell-2 (a second auditory neuron replacement therapy using different cell types) and Rincell-3 (focused on hair cell replacement), both in earlier feasibility stages. The company leverages its platform to generate cells for hearing restoration by reprogramming pluripotent cells into early-stage auditory cells needed for treatment.

Product and service3 records
1Rincell-1
CategoryRegenerative cell therapy — lead product
Description

A first-in-class regenerative cell therapy consisting of otic neural progenitors — cells one developmental stage away from becoming fully mature auditory neurons — generated from a single human donor's stem cells. Designed to regenerate auditory neurons and re-establish cochlear-to-brain connections in adults with severe-to-profound age-related hearing loss or auditory neuropathy who are eligible for cochlear implants under UK NICE guidance (TA566). In preclinical studies the cells reversed hearing loss and improved hearing threshold by approximately 40%.

2Rincell-2
CategoryRegenerative cell therapy — pipeline product
Description

Pipeline regenerative cell therapy programme targeting replacement of auditory neurons using a different type of starting cell than Rincell-1; currently at an earlier feasibility stage of development.

3Rincell-3
CategoryRegenerative cell therapy — pipeline product
Description

Pipeline regenerative cell therapy programme focused on auditory hair cell replacement for hearing restoration; currently in early feasibility stage of development.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Mytos
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-09-04
Description

Strategic manufacturing partnership to integrate Mytos' iDEM automated cell manufacturing platform across therapeutic applications including hearing loss, enabling scale-up from early clinical trials toward commercial-ready manufacturing.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-09
Description

Clinical partner for verified safe surgical access to central core of human cochlea. Professor Dan Jiang leads the Hearing Implant Centre at this institution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-13
Description

Collaboration to establish manufacturing processes and advance clinical trial techniques for stem cell therapy development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Rinri Therapeutics was spun out from the University of Sheffield based on Professor Marcelo Rivolta's research. Ongoing collaboration with Rivolta Laboratory for research and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partner with Professor Doug Hartley (Chief Medical Officer) from Nottingham University and Nottingham University Hospital NHS Trust. Collaboration on cochlear health measurement research and clinical trials.

6NHS Cochlear Implant Programs
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Delivery partner for first-in-human clinical trial of Rincell-1. Participants recruited through NHS cochlear implant centres in the UK.

rinri-therapeutics.com
Strategic tierStrategicTypeTechnology or Integration
Description

Collaboration on cochlear health measurement study using Advanced Bionics cochlear implant technology and AIM tablet system for daily self-assessment recordings by implant recipients.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

International research partner in coalition verifying safe surgical access to central core of human cochlea for therapeutic delivery.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

International research partner contributing data to vital research on cochlear microstructure enabling safe delivery of regenerative therapeutics.

10NIHR Nottingham Biomedical Research Centre
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on ground-breaking study to measure cochlear health using cochlear implant technology, led by Professor Douglas Hartley.

rinri-therapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gene therapy company developing treatments for sensorineural hearing loss, including inner ear hair cell and auditory nerve targets. Acquired by Eli Lilly in 2022 for $487M, making it the most directly comparable hearing loss therapeutic competitor to Rinri, with overlapping target indications and patient populations.

TypeDirect peer
Description

Clinical-stage biotechnology company developing gene therapies for hearing and balance disorders, including DB-OTO for otoferlin-related hearing loss. Acquired by Regeneron in 2023, positioning it as a direct competitor in the hearing loss therapeutic space with shared clinical-stage status and regenerative medicine approach.

TypeDirect peer
Description

Clinical-stage regenerative medicine company developing small-molecule approaches to activate progenitor cells for hearing restoration. While using a different modality (small molecules vs cell therapy), it targets the same indication (sensorineural hearing loss) with similar clinical-stage positioning.

4Otonomy
TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on the development of therapeutics for otology, including hearing loss and tinnitus. Targets similar ENT/otology indications with novel inner ear therapies, making it a relevant peer in the hearing loss therapeutic space.

TypeDirect peer
Description

Clinical-stage biotech company developing therapies for hearing loss disorders, including sensorineural hearing loss and rare auditory diseases. Overlapping therapeutic focus on inner ear disorders with both small molecule and gene therapy programs.

TypeEmerging player
Description

Biotechnology company developing regenerative therapies for hearing loss through small molecule approaches to regenerate hair cells. Represents an emerging alternative approach to hearing restoration with a different modality than Rinri's cell therapy but similar patient population.

TypeBroad incumbent
Description

Global leader in implantable hearing solutions including cochlear implants. While not developing regenerative cell therapies, Cochlear is the established incumbent addressing severe-to-profound hearing loss—the primary indication Rinri targets—and represents the standard-of-care benchmark.

TypeBroad incumbent
Description

Leading manufacturer of cochlear implant systems and hearing implant solutions. Serves as a broad incumbent in the hearing loss treatment space, providing the surgical infrastructure through which Rinri's Rincell-1 is delivered to patients.

TypeBroad incumbent
Description

Cochlear implant manufacturer and technology partner to Rinri for the cochlear health measurement study. Represents an established incumbent in the hearing implant space with overlapping clinical and patient engagement infrastructure.

TypeEmerging player
Description

Non-profit research organisation developing regenerative therapies for hearing loss. Represents an emerging player in the regenerative hearing loss space with overlapping scientific goals but different organisational structure and funding model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rinri Therapeutics

Regenerative Cell Therapyrinri-therapeutics.com

Rinri Therapeutics is a Sheffield-based, clinical-stage biotechnology company developing first-in-class regenerative cell therapies to reverse sensorineural hearing loss, with lead product Rincell-1 entering first-in-human trials for adults eligible for cochlear implants.

What Rinri Therapeutics does

Rinri Therapeutics is a clinical-stage biotechnology company developing first-in-class regenerative cell therapies for sensorineural hearing loss (SNHL). The company is headquartered at the Innovation Centre in Sheffield, United Kingdom, and was spun out of the University of Sheffield in 2019 based on Professor Marcelo Rivolta's foundational research into sensory stem cell biology, originally published in Nature in 2012. Around 90% of all hearing loss is sensorineural, and Rinri targets the neural component - auditory neuron damage - which cannot be addressed by existing hearing aids or cochlear implants. The company addresses a UK patient population estimated at 2.3 million with presbycusis and 13.5 million with auditory neuropathy spectrum disorder, within a global market of 430 million people with disabling hearing loss projected to reach 2.5 billion by 2050.

The company's core technology is the proprietary OSPREY platform, which reprograms pluripotent cells into early-stage auditory cells (otic neural progenitors) for therapeutic use. Lead product Rincell-1 comprises auditory neuron cells one developmental stage from maturity, derived from stem cells donated by a single human donor and stored in a stem cell bank. Rincell-2 targets the same neural replacement mechanism via alternative starting cells, while Rincell-3 focuses on auditory hair cell replacement. Preclinical work demonstrated approximately 40% hearing threshold improvement, and the company has funded research verifying safe surgical access to the central core of the human cochlea through an international coalition. Rincell-1 received UK MHRA approval for first-in-human trials in July 2025, MHRA Innovation Passport under ILAP, and FDA RMAT designation.

Rinri is currently pre-revenue with no commercial product pricing, generating no product revenue and operating with disclosed funding of £11.4 million in equity (a £1.4m seed round in May 2019 co-led by Boehringer Ingelheim Venture Fund and UCB Ventures, plus a £10m Series round in April 2021 from existing investors and the UK Government Future Fund) supplemented by Innovate UK grants and a $1m Grand Prize in October 2025. The go-to-market model is enterprise-direct: clinical trial delivery is conducted in partnership with NHS Cochlear Implant Programmes, and future commercialisation will target NHS trusts, hospitals, ENT surgeons, and audiologists in the UK, with regulatory pursuit in the US via FDA RMAT. Strategic ecosystem partners include Cell and Gene Therapy Catapult (manufacturing), Advanced Bionics (cochlear implant technology), NIHR Nottingham Biomedical Research Centre, and the University of Sheffield's Rivolta Laboratory.

Rinri Therapeutics firmographics

Firmographics
Name
Rinri Therapeutics
Legal name
Rinri Therapeutics Ltd
Website
https://rinri-therapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Rinri Therapeutics is a Sheffield-based, clinical-stage biotechnology company developing first-in-class regenerative cell therapies to reverse sensorineural hearing loss, with lead product Rincell-1 entering first-in-human trials for adults eligible for cochlear implants.
Ownership category
akta.pro rank

Rinri Therapeutics industry classification

Industry
Product category
Regenerative Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative cell therapy
  • Hearing loss treatment
  • Stem cell therapy
  • Otic neural progenitors
  • Sensorineural hearing loss

Where Rinri Therapeutics is headquartered

Location

Headquarters

HQ city
Sheffield
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Rinri Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Product Revenue: Rinri Therapeutics is a clinical-stage company developing regenerative cell therapies. No revenue is currently generated. The company plans to commercialize its pipeline of cell therapy products (Rincell-1, Rincell-2, Rincell-3) for the treatment of sensorineural hearing loss once approved.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Rinri Therapeutics product offering

Product offering

Core offering

Rinri Therapeutics develops regenerative cell therapies for sensorineural hearing loss, with lead product Rincell-1 (otic neural progenitors derived from human pluripotent stem cells) designed to regenerate auditory neurons and restore cochlear connections. The portfolio is built on the proprietary OSPREY platform and targets an unmet medical need unaddressed by hearing aids or cochlear implants.

Product overview

Rinri Therapeutics is developing a portfolio of first-in-class regenerative cell therapies for sensorineural hearing loss based on its proprietary OSPREY technology platform. The lead product, Rincell-1, is an otic neural progenitor cell therapy designed to regenerate auditory neurons and is currently in first-in-human clinical trials. The portfolio includes Rincell-2 (a second auditory neuron replacement therapy using different cell types) and Rincell-3 (focused on hair cell replacement), both in earlier feasibility stages. The company leverages its platform to generate cells for hearing restoration by reprogramming pluripotent cells into early-stage auditory cells needed for treatment.

Differentiator

Problem solved

Functional benefit

Brands

  • OSPREY: Proprietary platform for auditory cell development and manufacturing, enabling the development of a portfolio of differentiated products to tackle different aspects of hearing loss.
  • Rincell-1
  • Rincell-2
  • Rincell-3

Products and services

  • Rincell-1 A first-in-class regenerative cell therapy consisting of otic neural progenitors — cells one developmental stage away from becoming fully mature auditory neurons — generated from a single human donor's stem cells. Designed to regenerate auditory neurons and re-establish cochlear-to-brain connections in adults with severe-to-profound age-related hearing loss or auditory neuropathy who are eligible for cochlear implants under UK NICE guidance (TA566). In preclinical studies the cells reversed hearing loss and improved hearing threshold by approximately 40%.
  • Rincell-2 Pipeline regenerative cell therapy programme targeting replacement of auditory neurons using a different type of starting cell than Rincell-1; currently at an earlier feasibility stage of development.
  • Rincell-3 Pipeline regenerative cell therapy programme focused on auditory hair cell replacement for hearing restoration; currently in early feasibility stage of development.

Quantifiable outcome

  • Improved hearing threshold by approximately 40% in preclinical studies
  • +3 more outcomes

Companies that use Rinri Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles4 records

Rinri Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Rinri Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered strategic and core.

  • MytosstrategicTechnology or Integration · 4 September 2025Strategic manufacturing partnership to integrate Mytos' iDEM automated cell manufacturing platform across therapeutic applications including hearing loss, enabling scale-up from early clinical trials toward commercial-ready manufacturing.
  • Guy's and St Thomas' NHS Foundation TrustcoreStrategic or Co-development Partner · 9 November 2022Clinical partner for verified safe surgical access to central core of human cochlea. Professor Dan Jiang leads the Hearing Implant Centre at this institution.
  • Cell and Gene Therapy CatapultcoreStrategic or Co-development Partner · 13 May 2021Collaboration to establish manufacturing processes and advance clinical trial techniques for stem cell therapy development.
  • University of SheffieldcoreStrategic or Co-development PartnerRinri Therapeutics was spun out from the University of Sheffield based on Professor Marcelo Rivolta's research. Ongoing collaboration with Rivolta Laboratory for research and development.
  • University of NottinghamcoreStrategic or Co-development PartnerAcademic partner with Professor Doug Hartley (Chief Medical Officer) from Nottingham University and Nottingham University Hospital NHS Trust. Collaboration on cochlear health measurement research and clinical trials.
  • NHS Cochlear Implant ProgramscoreStrategic or Co-development PartnerDelivery partner for first-in-human clinical trial of Rincell-1. Participants recruited through NHS cochlear implant centres in the UK.
  • Advanced BionicsstrategicTechnology or IntegrationCollaboration on cochlear health measurement study using Advanced Bionics cochlear implant technology and AIM tablet system for daily self-assessment recordings by implant recipients.
  • Uppsala University (Sweden)strategicStrategic or Co-development PartnerInternational research partner in coalition verifying safe surgical access to central core of human cochlea for therapeutic delivery.
  • Western University (Canada)strategicStrategic or Co-development PartnerInternational research partner contributing data to vital research on cochlear microstructure enabling safe delivery of regenerative therapeutics.
  • NIHR Nottingham Biomedical Research CentrestrategicStrategic or Co-development PartnerCollaboration on ground-breaking study to measure cochlear health using cochlear implant technology, led by Professor Douglas Hartley.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Rinri Therapeutics competitors and assessment

Company assessment

Direct peers

  • Akouos: Gene therapy company developing treatments for sensorineural hearing loss, including inner ear hair cell and auditory nerve targets. Acquired by Eli Lilly in 2022 for $487M, making it the most directly comparable hearing loss therapeutic competitor to Rinri, with overlapping target indications and patient populations.
  • Decibel Therapeutics: Clinical-stage biotechnology company developing gene therapies for hearing and balance disorders, including DB-OTO for otoferlin-related hearing loss. Acquired by Regeneron in 2023, positioning it as a direct competitor in the hearing loss therapeutic space with shared clinical-stage status and regenerative medicine approach.
  • Frequency Therapeutics: Clinical-stage regenerative medicine company developing small-molecule approaches to activate progenitor cells for hearing restoration. While using a different modality (small molecules vs cell therapy), it targets the same indication (sensorineural hearing loss) with similar clinical-stage positioning.
  • Otonomy: Clinical-stage biopharmaceutical company focused on the development of therapeutics for otology, including hearing loss and tinnitus. Targets similar ENT/otology indications with novel inner ear therapies, making it a relevant peer in the hearing loss therapeutic space.
  • Sensorion: Clinical-stage biotech company developing therapies for hearing loss disorders, including sensorineural hearing loss and rare auditory diseases. Overlapping therapeutic focus on inner ear disorders with both small molecule and gene therapy programs.

Emerging players

  • Pipeline Therapeutics: Biotechnology company developing regenerative therapies for hearing loss through small molecule approaches to regenerate hair cells. Represents an emerging alternative approach to hearing restoration with a different modality than Rinri's cell therapy but similar patient population.
  • Hough Ear Institute: Non-profit research organisation developing regenerative therapies for hearing loss. Represents an emerging player in the regenerative hearing loss space with overlapping scientific goals but different organisational structure and funding model.

Broad incumbents

  • Cochlear Limited: Global leader in implantable hearing solutions including cochlear implants. While not developing regenerative cell therapies, Cochlear is the established incumbent addressing severe-to-profound hearing loss—the primary indication Rinri targets—and represents the standard-of-care benchmark.
  • MED-EL: Leading manufacturer of cochlear implant systems and hearing implant solutions. Serves as a broad incumbent in the hearing loss treatment space, providing the surgical infrastructure through which Rinri's Rincell-1 is delivered to patients.
  • Advanced Bionics: Cochlear implant manufacturer and technology partner to Rinri for the cochlear health measurement study. Represents an established incumbent in the hearing implant space with overlapping clinical and patient engagement infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Rinri Therapeutics social profiles

Digital presence

Rinri Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rinri Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Rinri Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rinri Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rinri Therapeutics

What does Rinri Therapeutics do?

Rinri Therapeutics develops regenerative cell therapies for sensorineural hearing loss, with lead product Rincell-1 (otic neural progenitors derived from human pluripotent stem cells) designed to regenerate auditory neurons and restore cochlear connections. The portfolio is built on the proprietary OSPREY platform and targets an unmet medical need unaddressed by hearing aids or cochlear implants.

Is Rinri Therapeutics a public or private company?

Rinri Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Rinri Therapeutics founded?

Rinri Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Rinri Therapeutics based?

Rinri Therapeutics is headquartered in Sheffield, United Kingdom, in the Europe region.

How does Rinri Therapeutics make money?

One revenue line is on record: therapeutic Product Revenue.

Who are Rinri Therapeutics's main competitors?

Direct peers on record are Akouos, Decibel Therapeutics, Frequency Therapeutics, Otonomy and Sensorion. Emerging players are Pipeline Therapeutics and Hough Ear Institute. Broad incumbents are Cochlear Limited, MED-EL and Advanced Bionics.

Does Rinri Therapeutics have an API?

No public API is recorded for Rinri Therapeutics.

What industry is Rinri Therapeutics in?

Rinri Therapeutics's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration, with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGroundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 showsRinri Therapeutics published a review on neural hearing loss, highlighting its role in hearing impairment and the lack of approved treatments. The company's Rincell-1, a regenerative cell therapy, is in a first-in-human trial, and the authors call for more research to improve diagnosis and outcomes.GlobeNewswireGroundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 showsRinri Therapeutics published a comprehensive review on neural hearing loss (NHL), highlighting its central role in hearing impairment and the lack of approved drug treatments for this condition affecting an estimated 7 million people globally. The company announced recent UK clinical trial approval for its first-in-class regenerative cell therapy Rincell-1, representing a significant step toward addressing this unmet medical need with cell therapies that could offer true repair and regeneration. The review calls for increased research, improved diagnostic testing, and biomarker development to address the likely underdiagnosis of NHL.BioSpaceGroundbreaking approaches such as cell therapies on the horizon for transformation of neural hearing loss, Rinri Therapeutics’ review1 showsRinri Therapeutics published a review on neural hearing loss, noting no approved drug treatments and sub-optimal standard devices. The company highlights its Rincell-1 cell therapy, which recently received a UK clinical trial application for a first-in-human trial. The authors call for more research to improve diagnosis and outcomes.BioSpaceMytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy TrialsMytos, a London-based biotechnology company automating cell manufacturing, announced new manufacturing collaborations with StemSight, Rinri Therapeutics, and Novadip to integrate its iDEM automated platform across diverse therapeutic applications including ocular diseases, hearing loss, and bone regeneration. The partnerships represent a validation of Mytos' technology, enabling each biotech company to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing. The collaborations reflect a broader industry shift toward automation in advanced cell therapies as the field matures toward patient-scale delivery.GlobeNewswireUK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing LossRinri Therapeutics received UK MHRA approval for its first-in-human trial of Rincell-1, a regenerative cell therapy for sensorineural hearing loss. The trial will involve 20 patients across three UK centres, with proof-of-concept data expected within 12 months. The company states no disease-modifying treatments currently exist for this condition.International Merit ScholarshipsOn the verge of reversing deafnessRinri Therapeutics, a biotechnology company spun out from the University of Sheffield, is preparing to initiate the world's first human clinical trial for Rincell-1, a regenerative cell therapy designed to reverse sensorineural hearing loss. The company has raised over £20 million and secured partnerships to overcome delivery challenges, with trials targeting patients with severe auditory nerve damage scheduled to begin in 2025. This development represents a significant shift from current symptom-management treatments toward potential biological restoration of hearing function.PR NewswireRinri Therapeutics Secures Innovate UK Funding Grant for £3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing LossRinri Therapeutics, a Sheffield-based biotechnology company developing a stem cell therapy for sensorineural hearing loss, announced on May 13, 2021 that it secured a £3.2 million grant from Innovate UK. The project, led by Rinri with the Cell and Gene Therapy Catapult and the Universities of Sheffield and Nottingham, will establish clinical trial manufacturing processes, nonclinical data and first-in-human trial techniques. Rinri is backed by Boehringer Ingelheim Venture Fund, UCB Ventures, BioCity, the University of Sheffield and the UK Future Fund.FinSMEsRinri Therapeutics Raises £10M in FundingRinri Therapeutics, a UK biotech firm developing a stem cell therapy for hearing loss, raised £10M from Boehringer Ingelheim Venture Fund, UCB Ventures, BioCity, and the UK Government Future Fund. The funding will support development of its therapy to reverse sensorineural hearing loss, with no current pharmacological options.PR NewswireRinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing LossRinri Therapeutics, a biotechnology company headquartered in Sheffield, UK, has raised £10 million in funding from existing investors Boehringer Ingelheim Venture Fund, UCB Ventures, and BioCity, alongside the UK Future Fund. The proceeds will advance the company's novel stem cell therapy targeting sensorineural hearing loss toward first-in-human clinical trials. The technology, spun out from the University of Sheffield, aims to repair damaged hair cells and auditory nerve tissue for which there are currently no pharmacological treatment options.